{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T14:25:09Z","timestamp":1769264709838,"version":"3.49.0"},"reference-count":33,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T00:00:00Z","timestamp":1706486400000},"content-version":"unspecified","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Open Heart"],"accepted":{"date-parts":[[2024,1,16]]},"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>To assess outcomes after cardiac surgery with biological valve replacement, valve repair or transcatheter aortic valve implantation (TAVI) in patients with atrial fibrillation (AF) in accordance with oral anticoagulant (OAC) treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>All patients in Sweden undergoing valvular intervention with AF were included. Associations between OAC exposure and cardiovascular (CV) events (composite of CV death, ischaemic stroke or systemic embolism) and major bleeding were investigated using Cox regression analysis. The analysis was separated in time periods of 0\u20133 and 3\u201312 months after discharge.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>4730 patients were included in the first time period, 54.0% had received a surgical biological valve prosthesis, 23.8% valve repair and 22.2% TAVI. Exposure to warfarin (comparator) was 62.3%, to non-vitamin K antagonist oral anticoagulants (NOACs) 10.0% and to no OAC 27.7%. NOAC exposure was associated with similar risk of the composite CV outcome and major bleeding from 0 to 3 months. No OAC was associated with increased risk of the composite CV outcome (HR 1.71; 95%\u2009CI 1.26 to 2.32) and similar risk of major bleeding. Further analysis of the bioprosthetic valve replacement subgroup indicated increased risk of CV death when exposed to NOAC (HR 2.58; 95%\u2009CI 1.15 to 5.78) and no OAC (HR 2.82; 95%\u2009CI 1.65 to 4.82) compared with warfarin from 0 to 3 months. No differences were seen between 3 and 12 months.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In this registry-based cohort study of patients with AF with severe valvular heart disease undergoing various valvular interventions, NOAC appears to be comparable with warfarin regarding efficacy and safety. Patients not receiving OAC had higher risk of CV events. NOAC was associated with increased CV death compared with warfarin in the surgical bioprosthetic valve replacement subgroup, illustrating the importance of being cautious when extrapolating data from one patient group to another. Further studies comparing NOAC and warfarin in the early postoperative phase are warranted, especially following surgical bioprosthetic valve replacement.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/openhrt-2024-002602","type":"journal-article","created":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T00:10:11Z","timestamp":1706573411000},"page":"e002602","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Thromboembolic and bleeding events after valvular intervention in patients with atrial fibrillation"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9335-9279","authenticated-orcid":false,"given":"Ebba-Louise","family":"Skogseid","sequence":"first","affiliation":[{"name":"Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2480-9547","authenticated-orcid":false,"given":"Gorav","family":"Batra","sequence":"additional","affiliation":[{"name":"Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden"},{"name":"Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Westerbergh","sequence":"additional","affiliation":[{"name":"Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claes","family":"Held","sequence":"additional","affiliation":[{"name":"Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden"},{"name":"Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Christersson","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,1,29]]},"reference":[{"key":"2025081709575641000_11.1.e002602.1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.014807"},{"key":"2025081709575641000_11.1.e002602.2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.19.8.937"},{"key":"2025081709575641000_11.1.e002602.3","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/eun369"},{"key":"2025081709575641000_11.1.e002602.4","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi505"},{"key":"2025081709575641000_11.1.e002602.5","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv163"},{"key":"2025081709575641000_11.1.e002602.6","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(94)00563-6"},{"key":"2025081709575641000_11.1.e002602.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.05.029"},{"key":"2025081709575641000_11.1.e002602.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.09.958"},{"key":"2025081709575641000_11.1.e002602.9","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa612"},{"key":"2025081709575641000_11.1.e002602.10","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab395"},{"key":"2025081709575641000_11.1.e002602.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2029603"},{"key":"2025081709575641000_11.1.e002602.12","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1056\/NEJMoa2111016","article-title":"Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR","volume":"385","author":"Van Mieghem","year":"2021","journal-title":"N Engl J Med"},{"key":"2025081709575641000_11.1.e002602.13","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1093\/eurheartj\/ehac242","article-title":"Apixaban vs. standard of care after Transcatheter aortic valve implantation: the ATLANTIS trial","volume":"43","author":"Collet","year":"2022","journal-title":"Eur Heart J"},{"key":"2025081709575641000_11.1.e002602.14","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jtcvs.2021.01.127","article-title":"Efficacy and safety of Edoxaban in patients early after surgical Bioprosthetic valve implantation or valve repair: a randomized clinical trial","volume":"165","author":"Shim","year":"2023","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2025081709575641000_11.1.e002602.15","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780030106"},{"key":"2025081709575641000_11.1.e002602.16","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"European heart rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"2025081709575641000_11.1.e002602.17","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.026714"},{"key":"2025081709575641000_11.1.e002602.18","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/clc.23178","article-title":"Efficacy and safety of Apixaban vs warfarin in patients with atrial fibrillation and prior Bioprosthetic valve replacement or valve repair: insights from the ARISTOTLE trial","volume":"42","author":"Guimar\u00e3es","year":"2019","journal-title":"Clin Cardiol"},{"key":"2025081709575641000_11.1.e002602.19","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2020-318753"},{"key":"2025081709575641000_11.1.e002602.20","doi-asserted-by":"crossref","first-page":"f20","DOI":"10.1093\/ehjcvp\/pvz073","article-title":"Safety and efficacy of non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: systematic review and meta-analysis of 22 studies and 440 281 patients","volume":"7","author":"Silverio","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2025081709575641000_11.1.e002602.21","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvw031"},{"key":"2025081709575641000_11.1.e002602.22","doi-asserted-by":"crossref","unstructured":"Hill NR , Sandler B , Bergrath E , et al . A systematic review of network meta-analyses and real-world evidence comparing Apixaban and Rivaroxaban in Nonvalvular atrial fibrillation. Clin Appl Thromb Hemost 2020;26. doi:10.1177\/1076029619898764","DOI":"10.1177\/1076029619898764"},{"key":"2025081709575641000_11.1.e002602.23","doi-asserted-by":"publisher","DOI":"10.1510\/icvts.2008.196675"},{"key":"2025081709575641000_11.1.e002602.24","doi-asserted-by":"publisher","DOI":"10.1177\/1076029614533144"},{"key":"2025081709575641000_11.1.e002602.25","doi-asserted-by":"publisher","DOI":"10.1160\/TH16-01-0007"},{"key":"2025081709575641000_11.1.e002602.26","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ahj.2019.10.017","article-title":"Four-year trends in oral anticoagulant use and declining rates of ischemic stroke among 194,030 atrial fibrillation patients drawn from a sample of 12 million people","volume":"220","author":"Maggioni","year":"2020","journal-title":"Am Heart J"},{"key":"2025081709575641000_11.1.e002602.27","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.17884"},{"key":"2025081709575641000_11.1.e002602.28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0262580","article-title":"Oral anticoagulant treatment after Bioprosthetic valvular intervention or Valvuloplasty in patients with atrial fibrillation-A SWEDEHEART study","volume":"17","author":"Christersson","year":"2022","journal-title":"PLoS One"},{"key":"2025081709575641000_11.1.e002602.29","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2010.198804"},{"key":"2025081709575641000_11.1.e002602.30","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.athoracsur.2020.05.104","article-title":"Postoperative atrial fibrillation after cardiac surgery: a systematic review and meta-analysis","volume":"111","author":"Eikelboom","year":"2021","journal-title":"Ann Thorac Surg"},{"key":"2025081709575641000_11.1.e002602.31","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1007\/s00392-020-01614-z","article-title":"Compared with matched controls, patients with postoperative atrial fibrillation (POAF) have increased long-term AF after CABG, and POAF is further associated with increased ischemic stroke, heart failure and mortality even after adjustment for AF","volume":"109","author":"Thor\u00e9n","year":"2020","journal-title":"Clin Res Cardiol"},{"key":"2025081709575641000_11.1.e002602.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2015.04.016"},{"key":"2025081709575641000_11.1.e002602.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.01.050"}],"container-title":["Open Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/openhrt-2024-002602","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,17]],"date-time":"2025-08-17T16:58:07Z","timestamp":1755449887000},"score":1,"resource":{"primary":{"URL":"https:\/\/openheart.bmj.com\/lookup\/doi\/10.1136\/openhrt-2024-002602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,29]]},"published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1136\/openhrt-2024-002602"],"URL":"https:\/\/doi.org\/10.1136\/openhrt-2024-002602","relation":{},"ISSN":["2053-3624"],"issn-type":[{"value":"2053-3624","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]}}}